How does Covid-19 vaccine heart inflammation risk compare to other vaccines?

Question

Accepted Answer

Covid-19 Vaccination Heart Inflammation Risk is Comparatively Low

The overall risk of heart inflammation, specifically myopericarditis, following a Covid-19 vaccination is very low. This risk is also smaller when compared to the incidence of heart inflammation associated with some vaccines for other diseases, such as smallpox.
Myopericarditis Rates After Covid-19 Vaccination

A study published in The Lancet Respiratory Medicine indicated that approximately 18 individuals per million doses of Covid-19 vaccine developed myopericarditis. This condition involves inflammation of the heart muscle, which can lead to permanent heart damage in some cases. The research analysed over 20 international studies, encompassing more than 395 million doses of Covid-19 vaccines, predominantly mRNA types.
Comparison with Other Vaccine Types

When contrasted with vaccinations for other diseases, the risk profile for Covid-19 vaccines is notable. For instance, non-Covid-19 vaccinations against influenza reported an average of 56 cases of heart inflammation per million doses. Furthermore, the study found that the rate of myopericarditis was significantly higher following smallpox vaccinations compared to Covid-19 vaccination. However, the incidence was not substantially different when comparing Covid-19 vaccines to those for influenza and other diseases.
Factors Influencing Myopericarditis Occurrence

Certain patterns emerged regarding the occurrence of myopericarditis post-vaccination. The study observed that myopericarditis was nearly four times more prevalent in individuals who received an mRNA Covid-19 vaccine compared to a non-mRNA vaccine. Additionally, the risk was higher for those receiving their second dose of the vaccine, as opposed to the first or third dose. The reported cases were also more common among males and individuals under the age of 30.
Risk from Covid-19 Infection vs. Vaccination

It is important to consider the risk of myopericarditis associated with contracting Covid-19 itself. The research highlighted that among 2.5 million hospitalised patients with Covid-19, 1.1 per cent experienced myopericarditis. While direct comparison of these figures is complex due to differing measurement methods and pre-existing conditions in patients, this data provides a reference point, suggesting that the benefits of vaccination likely outweigh the risks of such rare side effects.

Reading history

Hide →

This history is cleared when the page is closed.

How does Covid-19 vaccine heart inflammation risk compare to other vaccines?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

2

0

0

Share with friends